Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009

Remote Magnetic Navigation prominently featured on the HRS 2009 program

ST. LOUIS, May 11 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS)
said today that the Heart Rhythm 2009 formal program contains 21 podium and
poster presentations in which its Niobe system is either featured or discussed
regarding the treatment of complex cardiac arrhythmias. These presentations
include new efficacy data on the use of Stereotaxis' partnered magnetic
irrigated catheter at centers in Copenhagen and Hamburg.

Xu Chen, MD from Rigshospitalet in Copenhagen will present "Acute and
long-term outcomes of remote magnetic navigation for ablation of atrial
fibrillation using a magnetic irrigated ablation catheter" at a session
beginning at 10:30am on Friday, May 15, in Room 162. At the same session, Erik
Weissner of Asklepios Klinik St. Georg in Hamburg will present "Magnetically
navigated remote pulmonary vein isolation utilizing the second generation 3.5
mm magnetic irrigated tip catheter."

Also, Tamas Szili-Torok, MD of Erasmus Medical Center in Rotterdam and Jinjin
Wu, MD of the German Heart Center in Munich will present at Stereotaxis Booth
# 778 their experiences with the Niobe Remote Magnetic Navigation System and
the treatment of arrhythmias in children. These booth presentations are
separate from their independent conference presentations on the same subjects.

At Stereotaxis' booth, Dr. Szili-Torok will speak at 10:00am on Friday; his
presentation is titled, "Magnetic Navigation for the Treatment of Pediatric
Complex Congenital Arrhythmias." Dr. Wu will present at 3:00pm on Friday with
"Mapping of Atrial Tachycardia: Remote Navigation in Post-Operative Patients
with Congential Heart Disease." These presentations will provide a forum for
clinicians to share their pediatric experiences and techniques, and
demonstrate the growing interest of pediatric electrophysiologists in adding
magnetic navigation to their cardiology services.

Against this backdrop of clinical experience, Stereotaxis' Booth # 778 will
showcase the simplicity, safety, and efficacy of the Niobe Remote Magnetic
Navigation system, the enhanced productivity and procedural efficiency enabled
by Navigant 3.0 with QuikCAS, and the full Odyssey information management
solution. This includes the new Odyssey Workstation 3.0 software and the
Odyssey Cinema(TM) data management system for remote viewing and recording of
live interventional cases. This showcase will provide the most comprehensive
interactive demonstration of the full Odyssey solution to date, providing
clinicians with an opportunity to experience how Odyssey can enhance their
institutions' EP practice:

-- At two clinical forums during the conference, participants will be
able
to view and control the playback of complete EP cases on laptops
connected to the Odyssey Cinema server, underscoring the unprecedented
opportunities for training and sharing of best practices enabled by
this
peerless technology.
-- An Odyssey Connect network link will enable clinicians to use an
Odyssey
Workstation in Booth # 778 to remotely control a catheter in a Niobe
lab
in the company's St. Louis headquarters, 1,200 miles away.

-- The Odyssey Workstation will be available with a new, state-of-the-art
QuadHD display. Quad HD provides four times the resolution of prior,
high-definition displays, providing an incredible level of patient
detail.

"With our Odyssey Cinema product, we believe that we are building the first
true networked clinical environment that can improve care, enhance training
and education, maximize cath-lab efficiency, promote best practices and drive
hospital referrals," said Michael P. Kaminski, Stereotaxis' President and
Chief Executive Officer. "We are pleased with the progress we've made and will
continue our investment in Odyssey sales and marketing to take full advantage
of our first mover position in this space.

"We also look forward to highlighting the impressive new clinical results that
have been achieved with the Niobe Remote Magnetic Navigation system.
Stereotaxis' routine appearance in so many presentations and posters speaks to
the widespread adoption of our technology by leading electrophysiologists,
both for daily clinical practice and scientific discovery. This year we are
seeing an important increase in utilization for applications such as
ventricular tachycardia and navigation of the unpredictable anatomy associated
with congenital heart disease. Our customers report that magnetic navigation
is uniquely suited to these important market segments, highlighting the
platform's versatility in every chamber. We are confident that it will
continue to transform interventional medicine well into the future."

Heart Rhythm 2009, the Heart Rhythm Society's 30th Annual Scientific Sessions,
will be held at the Boston Convention and Exhibition Center, May 13 -- 16,
2009.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical
suite to enhance the treatment of arrhythmias and coronary artery disease. The
Stereotaxis system is designed to enable physicians to complete more complex
interventional procedures by providing image guided delivery of catheters and
guidewires through the blood vessels and chambers of the heart to treatment
sites. This is achieved using computer-controlled, externally applied magnetic
fields that govern the motion of the working tip of the catheter or guidewire,
resulting in improved navigation, shorter procedure time and reduced x-ray
exposure. The core components of the Stereotaxis system have received
regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently
involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, continued
acceptance for the Company's products in the marketplace, the effect of global
credit and economic conditions on the ability and willingness of customers to
purchase our systems, competitive factors, changes in government reimbursement
procedures, dependence upon third-party vendors, timing of regulatory approval
and return of the irrigated catheter to the market, and other risks discussed
in the Company's periodic and other filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the Company
will recognize revenue related to its purchase orders and other commitments in
any particular period or at all because some of these purchase orders and
other commitments are subject to contingencies that are outside of the
Company's control. In addition, these orders and commitments may be revised,
modified or canceled, either by their express terms, as a result of
negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.

Jim Stolze, Chief Financial Officer of Stereotaxis, Inc., +1-314-678-6105; or
Investors, Doug Sherk or Jenifer Kirtland, +1-415-896-6820, or Media, Steve
DiMattia, +1-646-201-5445, all of EVC Group, Inc., for Stereotaxis, Inc.